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Calbindin-D28K is a widely expressed calcium-buffering cytoplasmic protein
that is involved in many physiological processes. It has been shown to interact
with other proteins, suggesting a role as a calcium sensor. Many of the targets of
calbindin-D28K are of therapeutic interest: for example, inositol monophos-
phatase, the putative target of lithium therapy in bipolar disorder. Presented
here is the first crystal structure of human calbindin-D28K. There are significant
deviations in the tertiary structure when compared with the NMR structure of
rat calbindin-D28K (PDB entry 2g9b), despite 98% sequence identity. Small-
angle X-ray scattering (SAXS) indicates that the crystal structure better predicts
the properties of calbindin-D28K in solution compared with the NMR structure.
Here, the first direct visualization of the calcium-binding properties of calbindin-
D28K is presented. Four of the six EF-hands that make up the secondary
structure of the protein contain a calcium-binding site. Two distinct conforma-
tions of the N-terminal EF-hand calcium-binding site were identified using
long-wavelength calcium single-wavelength anomalous dispersion (SAD). This
flexible region has previously been recognized as a protein–protein interaction
interface. SAXS data collected in both the presence and absence of calcium
indicate that there are no large structural differences in the globular structure of
calbindin-D28K between the calcium-loaded and unloaded proteins.
1. Introduction
Calbindin-D28K is a major calcium-buffering cytoplasmic
protein that is expressed at particularly high levels in the
central nervous system (CNS) and absorptive epithelium
(gut and kidney; Schmidt, 2012). Calcium signalling is tightly
regulated and is involved in a myriad of physiological
processes, and consequently calcium deregulation is a key
factor in the pathogenesis of many diseases, such as Alzhei-
mer’s disease (Bojarski et al., 2008; Kook et al., 2014).
Calbindin-D28K was first identified in the intestine, colon,
kidney and uterus of Gallus gallus domesticus (chicken;
Wasserman et al., 1969), where it is involved in the transcel-
lular movement of calcium across the absorptive epithelium,
as found in the distal convoluted tubules of the kidney
(Lambers et al., 2006). Calbindin-D28K is also highly
expressed in the CNS, where it contributes up to 1.5% of
the total soluble protein (Christakos et al., 1989; Bergga˚rd,
Szczepankiewicz et al., 2002). In chicken kidney cells the
expression of calbindin-D28K is vitamin D dependent, and
this is true for other absorptive cells (Clemens et al., 1989);
however, it is not the case in the CNS (Arnold & Heintz,
1997). Calbindin-D28K has been reported to regulate the
depolarization-stimulated release of insulin from pancreatic
 cells through the regulation of the cytoplasmic calcium
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concentration (Sooy et al., 1999). It is well documented in the
literature that calbindin-D28K has neuroprotective properties
in the CNS (Yenari et al., 2001; Yuan et al., 2013; Sun et al.,
2011), and it has recently been demonstrated that its depletion
in an Alzheimer’s disease mouse model accelerates neuronal
loss, apoptosis and mitochondrial dysfunction (Kook et al.,
2014).
It has been shown that calbindin-D28K interacts with a
variety of proteins of therapeutic interest (Schmidt, 2012).
Calbindin-D28K binds and increases the catalytic activity of
inositol monophosphatase (IMPase), the putative target of
lithium therapy in bipolar disorder (Bergga˚rd, Szczepankie-
wicz et al., 2002). IMPase has a key role in the homeostasis of
the IP3 signalling cascade by replenishing free myo-inositol,
and inhibition of this enzyme by lithium gave rise to the
inositol-depletion hypothesis for the efficacy of lithium in the
treatment of bipolar disorder (Harwood, 2005). More recently,
IMPase inhibition has been shown to increase autophagy and
the clearance of peptides involved in the pathogenesis of both
Huntington’s and Parkinson’s diseases (Sarkar et al., 2005),
indicating that inhibition of the calbindin–IMPase interaction
may be of therapeutic benefit in these diseases. The calbindin–
IMPase interaction has been modelled in silico and the
information has been used to develop a series of novel peptide
inhibitors (Levi et al., 2013). Calbindin-D28K also exhibits
anti-apoptotic activity by binding to and inhibiting caspase-3
(Bobay et al., 2012; Bellido et al., 2000). Understanding the
structural basis of these interactions would offer possible new
therapeutic approaches to tackling these diseases.
Calbindin-D28K belongs to a superfamily of calcium-
binding proteins that includes calmodulin and troponin C. All
of these proteins have a high -helical content and share EF-
hand structures that constitute the calcium-binding domains.
Calbindin-D28K has a primary structure of 261 amino acids
(molecular mass of 30 kDa) and is encoded by the CALB1
gene. In 2006 an NMR structure of the calcium-loaded Rattus
norvegicus calbindin-D28K protein revealed the tertiary fold
of the protein for the first time: calbindin-D28K is mainly
-helical and the -helices make up six EF-hand motifs that
are held together in a single globular fold via hydrophobic
interactions (Kojetin et al., 2006). EF-hand motifs have a
helix–loop–helix topology and are a common structural char-
acteristic in calcium-binding proteins. As in most calcium-
binding proteins, the calcium ion is coordinated in the loop
region between the two helices of the EF-hand; in calbindin-
D28K a calcium ion is coordinated in four of the six EF-hand
motifs. EF-hands 1, 3, 4 and 5 bind calcium with high affinity
(A˚kerfeldt et al., 1996; Venters et al., 2003). It has been shown
that calbindin-D28K undergoes structural changes upon
calcium binding indicative of a calcium-sensing protein
(Bergga˚rd, Miron et al., 2002). However, both the apo and the
calcium-loaded protein have exposed hydrophobic residues on
the surface, indicating that calbindin-D28K interacts with
other proteins in both states (Bergga˚rd et al., 2000). The
high-resolution crystal structure of human calbindin-D28K
reported here confirms these secondary-structural findings
and also reveals some significant differences when compared
with the NMR structure of rat calbindin-D28K. The human
calbindin-D28K structure presented here allows the first direct
visualization of calcium ions bound by the protein.
2. Methods
2.1. Cloning and expression
The Escherichia coli codon-optimized human CALB1 gene
was synthesized and cloned into pET-15b using NcoI and
BamHI restriction sites (GenScript). A polyhistidine tag
followed by a rhinovirus (HRV) 3C protease cleavage
sequence was included in the synthetic construct directly 50 to
the calbindin-D28K start codon. The recombinant plasmid was
then transformed into E. coli Rosetta 2 (DE3) cells (Novagen)
and plated on LB agar containing 50 mg ml1 ampicillin. A
100 ml preculture was grown in LB broth (50 mg ml1 ampi-
cillin) overnight at 310 K with shaking at 200 rev min1. 10 ml
of the preculture was used to inoculate the main 1 l cultures,
which were grown at 310 K with shaking at 200 rev min1 to
an OD600 of 0.6. The cultures were incubated on ice for 2 h
before IPTG induction (0.4 mM) and incubation overnight at
298 K with shaking at 180 rev min1.
2.2. Purification
The cells were harvested and spun at 9500g for 20 min,
and the pellet was resuspended in sonication buffer [150 mM
NaCl, 1 mMMgCl2, 20 mM Tris pH 8.0 and protease-inhibitor
cocktail (cOmplete, EDTA-free, Roche)]. Cell lysis was
achieved by sonication for 5 min with 5 s intervals and DNA
was removed by the addition of a nonspecific endonuclease
(Benzonase nuclease, Sigma) and incubation on ice for 10 min.
The lysate was clarified at 30 000g for 20 min and the
supernatant was retained. His-tagged recombinant protein
was purified by cobalt-affinity chromatography (Talon metal-
affinity resin); the clarified lysate supernatant was incubated
with 10 ml binding buffer-equilibrated resin for 1 h at 277 K
(20 mM Tris pH 8.0, 150 mM NaCl, 10 mM imidazole). The
flowthough was removed and the resin was sequentially
washed with seven column volumes of binding buffer. The
bound proteins were then eluted with binding buffer
containing 250 mM imidazole. The His tag was removed by
incubation with HRV 3C protease overnight at 277 K. The
cleaved protein was further purified by size-exclusion chro-
matography on a Superdex G75 column in 5 mM Tris pH 8.0,
1 mM CaCl2, yielding 25–30 mg calbindin-D28K per litre of
culture.
2.3. Crystallization
The calbindin-D28K crystals that initially yielded the
calcium SAD phases were replicated from previously reported
crystallization conditions (crystallization condition 1:
60 mg ml1 protein in 1 mM CaCl2, 5 mM Tris pH 8.0 added
in a 1:1 ratio to 0.5M ammonium acetate, 0.1M bis-Tris pH
6.5, 24% PEG 3350; Zhang et al., 2008). The crystal structure
reported here was obtained using the JCSG+ Screen (Newman
et al., 2005) from Molecular Dimensions [crystallization
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condition 2: 0.1M potassium thiocyanate, 30%(w/v) PEG 2000
MME]. Recombinant calbindin-D28K was concentrated to
40 mg ml1 in 1 mM CaCl2, 5 mM Tris pH 8.0. Crystal-
lization was performed in MRC 2-well crystallization plates
(Swissci) with a reservoir volume of 50 ml and a drop volume
of 0.2 ml consisting of a 1:1 ratio of precipitant solution and
protein solution. The crystallization plates were incubated at
293 K and calbindin-D28K crystals grew within a week.
2.4. Data collection and processing
X-ray diffraction data were collected from calbindin-D28K
crystals grown under condition 1 on the long-wavelength
macromolecular crystallography beamline I23 at Diamond
Light Source (DLS; Wagner et al., 2016). The calcium SAD
phasing experiment was performed at a wavelength of 3.02 A˚,
close to the Ca K absorption edge ( = 3.07 A˚). A total of 8000
images from two 400 sweeps were collected with a 0.1 s
exposure time using the inverse-beam method. The data were
processed with the DIALS and AIMLESS packages (Evans &
Murshudov, 2013; Winter et al., 2018). An anomalous
substructure of five Ca atoms could be determined with
SHELXD (Sheldrick, 2008). While three of the Ca atoms had
close to full occupancy, the remaining two Ca atoms had
estimated occupancies of around 50% each. After density
modification, over 90% of the structure could be built into
the resulting experimental electron-density map. However,
although the structure was solvable, it could not be refined
owing to ambiguous N-terminal electron density. Therefore,
X-ray diffraction data from a calbindin-D28K crystal grown
using crystallization condition 2 were also collected on the I03
beamline at Diamond Light Source. Data were collected at
100 K with 30% glycerol as a cryoprotectant. 1040 images
were collected with an ! oscillation of 0.10 and an exposure
time of 0.1 s per image at a wavelength of 0.976 A˚. Diffraction-
intensity data were indexed, integrated and scaled using the
autoPROC toolbox (Table 1; Vonrhein et al., 2011). Molecular
replacement with the calcium SAD model yielded a phasing
solution using Phaser (McCoy et al., 2007). After cycles of
model building and refinement using Buccaneer and the CCP4
suite of programs (Cowtan, 2012; Murshudov et al., 2011;
Emsley et al., 2010), building of the final model was completed
in Coot and the model was refined with BUSTER v.2.10.2.
2.5. SEC-SAXS
SEC-SAXS was performed on the B21 beamline at
Diamond Light Source. Calbindin-D28K samples were
dialyzed for 12 h at 277 K against 1 l sample-dialysis buffer
(20 mM Tris pH 7.8, 150 mM NaCl with or without 3 mM
CaCl2) prior to experiments. A 45 ml sample of 11.5 mg ml
1
calcium-loaded calbindin-D28K or 12.2 mg ml1 unloaded
calbindin-D28k was injected onto a Shodex KW402 size-
exclusion column pre-equilibrated with dialysis buffer and run
at a flow rate of 0.16 ml min1. Intensity [I(q)] data were
collected as the eluate passed through the X-ray beam and
were plotted against q = 4sin/. The system operated with
an exposure time of 3 s at 12.4 keV (1 A˚) using a PILATUS
2M detector located at a distance of 4 m. Data were analysed
using ATSAS and SCA˚TTER (Franke et al., 2017; Franke &
Svergun, 2009; Kozin & Svergun, 2001). The FoXS web server
was used to compute the theoretical scattering profile from
NMR and crystal structures of calbindin-D28K for compar-
ison with the experimental data (Schneidman-Duhovny et al.,
2013, 2016). No changes were made to the calbindin-D28K
protein models used. However, the solvent molecules were
removed from the structures. The structures were used as
deposited. PDB entry 6fie has an extra three residues at the
N-terminus owing to cleavage of the His tag at the 3C protease
cleavage sequence. The SAXS data and analysis have been
deposited in the Small Angle Scattering Biological Data Bank
(Valentini et al., 2015; accession codes SASDDL6 for calcium-
loaded calbindin-D28K and SASDDM6 for unloaded
calbindin-D28K).
3. Results
3.1. Crystal structure of calbindin-D28K
Refinement statistics for the calbindin-D28K crystal struc-
ture (PDB entry 6fie; crystal condition 2) determined to a
resolution of 1.51 A˚ are presented in Table 1. The disorder in
the first calcium-binding site is reflected in the weaker side-
chain electron density in the N-terminal EF-hands, accounting
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Table 1
Crystallographic statistics and merging statistics produced by autoPROC
for PDB entry 6fie (crystal condition 2) and AIMLESS for the calcium
SAD data set (crystallization condition 1).
Values in parentheses are for the highest shell.
Data set PDB entry 6fie Calcium SAD
Beamline I03, DLS I23, DLS
Unit-cell parameters
a (A˚) 84.62 88.09
b (A˚) 104.22 100.17
c (A˚) 29.61 30.69
 () 90 90
 () 90 90
 () 90 90
Space group P21212 P21212
Wavelength (A˚) 0.976 3.02
Resolution range (A˚) 29.61–1.51 (1.54–1.51) 50.9–1.98 (2.03–1.98)
No. of observations 151983 (7621) 119199 (3772)
No. of unique observations 41505 (2048) 15168 (848)
Completeness (%) 99.1 (99.8) 99.7 (60.2)
Multiplicity 3.7 (3.7) 7.9 (4.4)
Anomalous completeness (%) 91.6 (93.2) 73.8 (57.0)
Anomalous multiplicity 2.0 (2.0) 4.1 (2.3)
Rmerge (%) 0.041 (0.852) 0.090 (0.970)
Rp.i.m.(I) (%) 0.024 (0.506) 0.030 (0.330)
CC1/2 0.998 (0.365) 0.997 (0.743)
hI/(I)i 14.4 (1.4) 13.8 (1.8)
Refinement BUSTER v.2.10.2
Resolution range (A˚) 21.90–1.51
Rcryst 0.202
Rfree 0.236
No. of protein atoms 4127
No. of ligand atoms 4
No. of solvent atoms 180
Mean B factor (A˚2) 37
R.m.s.d., bond lengths (A˚) 0.01
R.m.s.d., bond angles () 1.02
for the relatively high RMSZ score for this structure compared
with other X-ray structures determined at similar resolution.
The calcium SAD structure determined from crystal condition
1 allowed direct visualization of the Ca atoms (Supplementary
Fig. S1). This revealed for the first time that there are two
conformations, with the calcium ions located 4.7 A˚ apart, in
the N-terminal EF-hand 1 (Fig. 1). Only one of these calcium-
binding conformations was visible in the electron density for
both crystal conditions. Owing to the increased noise in this
region, the calcium-coordinating waters were not modelled
around the disordered EF-hand 1. Zhang et al. (2008) deter-
mined the space group to be C2 for a crystal obtained using
crystallization condition 1. However, the crystal obtained from
repeated use of this condition belonged to space group P21212.
3.2. Calcium binding
At a Ca2+ concentration of 1 mM, calbindin-D28K binds
four calcium ions at the EF1, EF3, EF4 and EF5 motifs with a
pentagonal bipyramidal coordination geometry (Fig. 2). The
coordinating residues, starting from the N-terminal binding
residues of the calcium-binding loops, are aligned in Table 2.
Five amino-acid residues, a backbone interaction and a water
molecule complete the coordination of calcium in the EF1,
EF4 and EF5 motifs. In contrast, the EF3 motif utilizes an
interaction at Glu119 (position 9) instead of a water molecule
to complete the coordination of calcium. At position 12 all
four calcium-binding loops possess a conserved glutamate side
chain that acts as a bidentate coordinating residue. There are
also non-calcium-binding conserved residues within the EF
loops; there is a conserved glycine at position 6 and either a
leucine or isoleucine at position 8. There were no detectable
differences in the SAXS scattering curves for calcium-loaded
calbindin-D28K and the calcium-unloaded protein (Supple-
mentary Fig. S2), indicating that the protein retains the same
‘kidney-bean’ shape on calcium binding.
3.3. Structural comparison
Calculated scattering curves for PDB entry 6fie and all ten
models from PDB entry 2g9b (Kojetin et al., 2006) were
compared with the X-ray scattering curve of calbindin-D28K
in solution. Interestingly, the crystal structure curve fitted the
SAXS curve better than the NMR models, with a lower 	
value of 1.19 versus a range of 1.98–2.43 for the NMR models
(Fig. 3a). Pairwise alignment with FATCAT (Ye & Godzik,
2003) calculated an r.m.s.d. of 3.2 A˚ between the crystal
structure and the NMR structure (Fig. 3b). The distance
between pairs of C atoms in EF1 and EF6 of the calbindin
models indicates that the NMR model is more compact
compared with the crystal structure. For instance, the distance
between Lys34 C and Lys224 C is 35.59 and 27.79 A˚ for PDB
entries 6fie and 2g9b (model 2), respectively (Fig. 3c).
4. Discussion
Calbindin-D28K is a widely expressed calcium-binding protein
that possesses a multiplicity of physiological functions. Its
expression is particularly high in the central nervous system
and absorptive epithelial tissues, where it buffers and facil-
itates the movement of calcium (Clemens et al., 1989; Schmidt,
2012; Wasserman et al., 1969). Recent work has hinted at a
possible protective role of calbindin-D28K in inhibiting
apoptosis and necrosis, and in slowing the pathogenesis of
neurodegenerative diseases such as Alzheimer’s disease
(Yuan et al., 2013; Yenari et al., 2001; Sun et al., 2011; Kook et
al., 2014; Bellido et al., 2000). Not only does calbindin-D28K
act as a buffer for calcium ions, but it has also been shown to
interact with multiple protein targets to modulate their func-
tion or catalytic activity (Shamir et al., 2005; Bergga˚rd,
Szczepankiewicz et al., 2002; Lutz et al., 2003). Here, we report
the first X-ray structure of calbindin-D28K, allowing the first
detailed high-resolution analysis of its calcium-binding prop-
erties. The X-ray structure of human calbindin-D28K also
displays significant structural differences when compared with
the previously published NMR structure of the rat calbindin-
D28K molecule. The human and rat isoforms have a sequence
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Figure 1
The two Ca atoms in EF1 from the substructure coordinates. The distance
between the peaks is shown. There was an estimated occupancy of 50%
for each calcium. The Ca atom in pink is that refined in PDB entry 6fie.
Table 2
The aligned calcium-binding loops from calbindin-D28K starting from the first calcium-binding residue.
Calcium-binding residues are highlighted in bold. A backbone carbonyl group binds the calcium at position 7.
Amino-acid position starting from the first calcium-binding residue
EF-hand 1 2 3 4 5 6 7 8 9 10 11 12 Water
EF1 Asp Ala Asp Gly Ser Gly Tyr Leu Glu Gly Lys Glu Y
EF3 Asp Thr Asp His Ser Gly Phe Ile Glu Thr Glu Glu N
EF4 Asp Ser Asn Asn Asp Gly Lys Leu Glu Leu Thr Glu Y
EF5 Asp Gln Asp Gly Asn Gly Tyr Ile Asp Glu Asn Glu Y
identity of 98%. Gln44, Asp225, Thr232 and Cys257 in human
calbindin-D28K are changed to Leu44, Glu225, Ser232 and
Ser257 in the rat isoform. These residues are solvent-exposed
and do not seem to explain the structural difference observed
between the two structures. Human calbindin-D28K consists
of six EF-hand motifs arranged in three pairs that maintain a
globular structure stabilized by hydrophobic interactions
(Kojetin et al., 2006). Four EF-hands bind calcium at a
concentration of 1 mM in the crystallization buffer, a
concentration that is significantly higher than the usually
nanomolar physiological (cytosolic) concentration. This would
imply that the structure presented here represents a calcium-
saturated form of the protein with respect to physiological
conditions (Berridge, 1997). There are differences in the
calcium-binding residues between the individual calcium-
binding loops; despite these differences in primary structure,
macroscopic studies have indicated that calbindin-D28K binds
calcium in a nonsequential, parallel manner (Bergga˚rd, Miron
et al., 2002). However, other spectroscopic studies have indi-
cated the opposite, that calcium binding is not simultaneous
(Venters et al., 2003), and the differences in the calcium-
binding mechanisms observed in the crystal structure support
this. EF3 is the only calcium-binding loop that does not use
water in the pentagonal bipyramidal coordination of the
calcium ion; Glu119 at position 9 instead fulfils this role.
Interestingly, both EF1 and EF4 also have glutamate at
position 9 of the loop, but these residues are not involved in
calcium coordination. Compared with the existing NMR
model of calbindin-D28K, the X-ray structure is less compact,
with the intramolecular distances increased by several
a˚ngstro¨ms across the molecule. This less condensed model was
validated by SAXS, as the scattering curve of the protein in
solution was better predicted by the crystal structure. This is
surprising as it is often assumed that crystal structures would
be more compact than solution NMR structures owing to
crystal-packing restraints. The high overall r.m.s.d. value of
3.2 A˚ also reflects significant structural differences between
the X-ray structure and the NMRmodel. There are substantial
differences in side-chain conformations both across the
molecule and within the calcium-binding loops. Calcium
binding at the N-terminal EF-hand (EF1) motif (where the
electron density is more disordered) appears to be more
flexible that in the other calcium-binding loops. The calcium
SAD experiment indicated that there are two distinct calcium
positions in the N-terminal EF-hand, with the calcium ions
bound 4.7 A˚ apart in the crystal form reported by Zhang et al.
(2008) (crystallization condition 1). Although the calcium
SAD data did yield a phasing solution, the dual calcium-
binding geometry precluded full structure refinement.
Consequently, new crystal-growth conditions potentially
favouring a single conformation
were explored, yielding crystal
condition 2 in which residues are
visible at the N-terminus. Never-
theless, the N-terminal flexibility
still manifests as structural
disorder, with higher temperature-
factor values in this region. It was
not possible to build the two
conformations into the electron
density, and only one calcium-
binding site is visible in the final
structure. The flexibility of this
region could be important in
facilitating interactions with other
proteins. Site-directed mutagen-
esis studies have previously
revealed that inositol monophos-
phatase (IMPase) binds to aspar-
tate residues 24 and 26 in this
flexible calcium-binding loop
(EF1) of calbindin-D28K (Levi et
al., 2013). Here, we demonstrate
that Asp24 and Asp26 are
involved in calcium binding. It
has previously been demon-
strated that the potentiation of
IMPase catalytic activity by
calbindin-D28K occurs irrespec-
tive of calcium being present
(Bergga˚rd, Szczepankiewicz et
al., 2002). The peptide-binding
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Figure 2
The four EF-hand calcium-binding loops of calbindin-D28K. Calcium-binding amino acids, water molecules
and calcium ions are shown, while the rest of the structure is illustrated by a cartoon representation. Each
calcium ion is coordinated with a pentagonal bipyramidal coordination geometry, the bonds for which are
represented by a dotted line. The EF1 calcium is coordinated by Asp24, Asp26, Ser28, Tyr30, Glu35 and
water, the EF3 calcium by Asp111, Asp113, Ser115, Phe117, Glu119 and Glu122, the EF4 calcium by
Asp155, Asn157, Asp159, Lys161, Glu166 and water, and the EF5 calcium by Asp199, Asp201, Asn203,
Tyr205, Glu210 and water.
fragment of Ran-binding protein M has also been shown to
induce large chemical shifts in the NMR spectrum of
calbindin-D28K in the flexible N-terminal region (Lutz et al.,
2003). Docking simulations predict the binding of IMPase at
the grooved structure between the N- and C-terminal EF-hand
bundles of calbindin-D28K, where the X-ray structure differs
the most from the NMR model.
The SAXS scattering curves of calcium-loaded and
unloaded calbindin-D28K are essentially identical, indicating
similar globular structures for both states and no increase in
flexibility. Because SAXS is a low-resolution technique that
can only be used to monitor large conformation changes, these
findings do not preclude significant changes on the intra-
molecular scale.
5. Conclusion
We present here the first X-ray structure of calbindin-D28K at
near-atomic resolution. Elucidation of the calcium coordina-
tion geometry in the EF-hand loops is consistent with previous
reports that the protein has four calcium-binding sites.
Calcium SAD at long wavelength demonstrated that the
N-terminal EF-hands are particularly flexible and possesses
two calcium-binding conformations. Residues that have
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Figure 3
(a) Log10 SAXS intensity versus scattering vector q. The plotted range represents the positive-only data within the specified q-range (red). The calculated
FoXS scattering curve of PDB entry 6fie (blue) and calculated FoXS scattering curves for the first five models of PDB entry 2g9b (green, turquoise, pink,
orange and black). (b) FATCAT pairwise alignment and superimposition (PDB entry 6fie, red; PDB entry 2g9b, orange); there is a 90 rotation between
the two images. (c) Measurement of the distance between the C atoms of Lys34 and Lys221; the distance is shown in A˚
previously been shown to be involved in protein–protein
interactions are demonstrated to also coordinate calcium,
potentially bestowing a calcium-sensor function on calbindin-
D28K. Calbindin-D28K maintains the same globular shape in
both the calcium-loaded and unloaded forms. There is also no
significant increase in the flexibility of the calbindin-D28K
protein in the unloaded form. Intriguingly, PDB entry 6fie is a
better model of calbindin-D28K in solution, as the X-ray
scattering curve produced by the protein is better predicted by
the crystal structure than by the previously published NMR
model (PDB entry 2g9b). We surmise that the high-resolution
X-ray structure of calbindin-D28K presented here should be
used as the model of choice for future experimentation and in
silico modelling.
6. Related literature
The following reference is cited in the Supporting information
for this article: Thorn & Sheldrick (2011).
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